He Ren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6954437/publications.pdf

Version: 2024-02-01

42 papers	2,275 citations	201674 27 h-index	223800 46 g-index
47 all docs	47 docs citations	47 times ranked	4326 citing authors

#	Article	IF	Citations
1	Human FOXP3 and tumour microenvironment. Immunology, 2023, 168, 248-255.	4.4	33
2	VHH212 nanobody targeting the hypoxia-inducible factor 1Î± suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer <i>in vivo</i>. Cancer Biology and Medicine, 2021, 18, 772-787.	3.0	15
3	Epithelial cells mimic immune cells: a novel path toward tumor immunotherapy. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	1
4	Somatic gene mutation signatures predict cancer type and prognosis in multiple cancers with pan-cancer 1000 gene panel. Cancer Letters, 2020, 470, 181-190.	7.2	29
5	An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Letters, 2020, 495, 200-210.	7.2	30
6	Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 149.	17.1	10
7	PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduction and Targeted Therapy, 2020, 5, 38.	17.1	75
8	Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1Î± Inhibitor Impairs Pancreatic Tumor Growth. ACS Nano, 2019, 13, 2176-2189.	14.6	46
9	LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygenâ€“Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Clinical Cancer Research, 2019, 25, 4091-4103.	7.0	35
10	Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Journal of Experimental Medicine, 2019, 216, 656-673.	8.5	31
11	Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials, 2018, 158, 44-55.	11.4	29
12	Interleukin 35 Expression Correlates With Microvessel Density inÂPancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Gastroenterology, 2018, 154, 675-688.	1.3	89
13	A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biology and Medicine, 2018, 15, 70.	3.0	9
14	Control of Treg cell homeostasis and immune equilibrium by Lkb1 in dendritic cells. Nature Communications, 2018, 9, 5298.	12.8	42
15	Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nature Communications, 2017, 8, 14035.	12.8	95
16	Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World Journal of Surgical Oncology, 2017, 15, 48.	1.9	33
17	HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Cancer Letters, 2017, 393, 113-124.	7.2	26
18	A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Letters, 2017, 402, 61-70.	7.2	51

#	Article	IF	Citations
19	ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. Cancer Research, 2017, 77, 874-885.	0.9	45
20	Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials. Journal of Berry Research, 2017, 7, 147-161.	1.4	45
21	Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer. International Journal of Molecular Sciences, 2017, 18, 622.	4.1	46
22	Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes. Oncotarget, 2016, 7, 13717-13729.	1.8	40
23	Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2016, 17, 799.	4.1	70
24	Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma. Cancer Letters, 2016, 378, 87-96.	7.2	25
25	IGFBP2 Activates the NF-Î²B Pathway to Drive Epithelialâ€“Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2016, 76, 6543-6554.	0.9	84
26	Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials, 2016, 102, 187-197.	11.4	208
27	SCF, Regulated by HIF-1Î±, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression. PLoS ONE, 2015, 10, e0121338.	2.5	27
28	Co-delivery of HIF1Î± siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials, 2015, 46, 13-25.	11.4	208
29	Nanospheres of doxorubicin as cross-linkers for a supramolecular hydrogelation. Scientific Reports, 2015, 5, 8764.	3.3	21
30	Multiple Layerâ€byâ€Layer Lipidâ€Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Advanced Functional Materials, 2015, 25, 788-798.	14.9	96
31	LASP1 Is a HIF1Î± Target Gene Critical for Metastasis of Pancreatic Cancer. Cancer Research, 2015, 75, 111-119.	0.9	90
32	Inhibition of HIF-1Î± by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 2250-2262.	1.8	110
33	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 27816-27831.	1.8	20
34	CypA, a Gene Downstream of HIF-1Î±, Promotes the Development of PDAC. PLoS ONE, 2014, 9, e92824.	2.5	30
35	Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Medical Oncology, 2014, 31, 857.	2.5	29
36	Gemcitabine induced supramolecular hydrogelations of aldehyde-containing short peptides. RSC Advances, 2014, 4, 34729-34732.	3.6	22

#	Article	IF	Citations
37	Hypoxia inducible factor (HIF)-1Î± directly activates leptin receptor (Ob-R) in pancreatic cancer cells. Cancer Letters, 2014, 354, 172-180.	7.2	41
38	Hypoxia-Inducible Factor-1 Promotes Pancreatic Ductal Adenocarcinoma Invasion and Metastasis by Activating Transcription of the Actin-Bundling Protein Fascin. Cancer Research, 2014, 74, 2455-2464.	0.9	143
39	Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis, 2014, 35, 2283-2290.	2.8	23
40	Resection or cryosurgery relates with pancreatic tumor type: Primary pancreatic cancer with previous non-pancreatic cancer or secondary metastatic cancer within the pancreas. Pancreatology, 2014, 14, 64-70.	1.1	6
41	The CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic adenocarcinoma. Journal of Cellular Biochemistry, 2013, 114, 2603-2611.	2.6	15
42	Hypoxia-inducible factor (HIF)-1Â directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis, 2008, 29, 1853-1861.	2.8	120